Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
about
Translatability scoring in drug development: eight case studiesDabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisonsPharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacementCardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.Direct thrombin inhibitors.New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplastyAnticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly.Is there adequate provision of venous thromboembolism prophylaxis following hip arthroplasty? An audit and international surveyPharmacological basis and clinical evidence of dabigatran therapy.New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disordersEffects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarinA preliminary assessment of the critical differences between novel oral anticoagulants currently in development.The status of new anticoagulants.Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects.Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasisIntracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studiesThe prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.Recent developments in the use of oral anticoagulants.Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.Venous thromboembolism: a clinical review.Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.New anticoagulants for the prevention of venous thromboembolism.Novel oral anticoagulants. Part II: direct thrombin inhibitors.Laboratory assessment of new anticoagulants.Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery.New anticoagulants: how to deal with treatment failure and bleeding complications.Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk.Oral factor Xa and direct thrombin inhibitors: a clinical perspective.Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
P2860
Q22241760-11F13610-864C-452E-AC3E-1127E3D0FDFEQ26995635-C724FCD6-1242-498E-9256-ED0C1429C953Q28245267-D93E2663-8AF7-4380-8928-E239168ABBEFQ30680968-1FF9F538-CCC6-418D-9E27-FC7F437CDB27Q33381801-004691E4-D523-4C5A-B6E5-E758288E586DQ33389966-4AE97D4B-A7CF-467D-AE32-F4D982C88C37Q33393692-D5B2C245-C30F-4112-B3A3-D785182FA5D2Q33891915-323FE071-CF34-4000-8191-FF335412F4D1Q34017336-2DF1EF0C-08BE-4E18-9A58-071355A0D899Q34252907-B24E922E-3FAF-4937-9C9E-972A889F363EQ34611004-722C0474-BD24-45F4-9349-886E8404538DQ34638063-42C4AA67-247A-4DE0-B734-7E77877099BEQ34667594-8F2DD1B7-C3F4-47B1-88BB-D64117576CF1Q35588756-32B6CCE1-72B1-429E-AAC6-AA8632683F11Q35685099-9384D9B5-1C61-4231-A10F-489842B06F41Q35739671-ABF9B57A-5C25-4122-95C3-D8AE1FEE28B8Q35827856-4168133D-E1FC-4353-92E9-72F6826991FAQ36042279-7D4AD5F9-DAAB-4A08-89E1-7F7632C0E8A2Q36229356-447A8D2F-80C9-478E-879D-00509E4DEBADQ36520745-CB653C31-1E64-4BBA-A22D-A5DCB5451454Q36791747-77EF6CAE-0A07-4EC8-8F8C-8755BB5B08A8Q36843779-9F102F53-116A-46CC-B192-7C7D13DC4FDCQ36984232-804267C4-42FF-46FC-9B0F-F17E2AF94EBDQ37316352-4FF46D72-55B3-4421-AB4A-B986B433B903Q37428883-B51BBB1D-C31E-4358-97A1-88436257A008Q37528463-E42B8267-1BD6-40F6-A5E2-E42EB139105EQ37569325-B7906003-B4C2-48BF-9802-5CA8048DD2A5Q37583245-E3015BF4-BD17-477A-AEB9-98F7EB746375Q37702728-E0409044-C266-40ED-865D-0B0CA975B28FQ37743508-909069E4-46A4-4074-ABC4-AD3E8BD977F2Q37763535-6E4AB6DA-14DC-47B6-98AE-E774A00682A0Q37810102-F26817CB-FA09-44FF-A8B0-9339A1F0C859Q37834646-05169F26-628C-49CF-8916-C70EE02EB4B3Q37858373-F23C85F9-1999-4C74-9587-86DA65C28C26Q37876398-0791795A-FE36-46DD-B249-CC7841DB3843Q37900670-7E1D0BEC-BCB3-4A69-824F-D102E4F039B2Q37924500-4774500C-9EE3-47BF-805F-026ED70DC658Q37970791-E99400BD-0A77-4317-B7B1-465EE0424A03Q37978093-BB68A09D-ECB0-4757-A9A6-326BBEBAFE12Q37990317-C15D5099-1C77-4C86-81F4-A30C96CC1654
P2860
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Dose escalating safety study o ...... tal hip replacement: BISTRO I.
@en
Dose escalating safety study o ...... tal hip replacement: BISTRO I.
@nl
type
label
Dose escalating safety study o ...... tal hip replacement: BISTRO I.
@en
Dose escalating safety study o ...... tal hip replacement: BISTRO I.
@nl
prefLabel
Dose escalating safety study o ...... tal hip replacement: BISTRO I.
@en
Dose escalating safety study o ...... tal hip replacement: BISTRO I.
@nl
P2093
P1476
Dose escalating safety study o ...... tal hip replacement: BISTRO I.
@en
P2093
B I Eriksson
J Stangier
K Hermansson
V Kohlbrenner
P304
P356
10.1111/J.1538-7836.2004.00890.X
P50
P577
2004-09-01T00:00:00Z